Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) treatment is still challenging, and immunotherapy is a potential approach in this tumor subtype. Cetuximab is an IgG1 monoclonal antibody (mAb) directed against Epidermic Growth Factor Receptor (EGFR), a protein overexpressed in a subgroup of TNBC patients and as...

Descripción completa

Detalles Bibliográficos
Autores principales: Juliá, Estefanía Paula, Mordoh, José, Levy, Estrella Mariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408037/
https://www.ncbi.nlm.nih.gov/pubmed/32605193
http://dx.doi.org/10.3390/cells9071573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408037/
https://www.ncbi.nlm.nih.gov/pubmed/32605193
http://dx.doi.org/10.3390/cells9071573

Ejemplares similares